These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12738677)

  • 61. The assessment of proliferating cell nuclear antigen immunostaining in myelodysplastic syndromes and its prognostic significance.
    Alexandrakis MG; Passam FH; Dambaki K; Passam AM; Nalbanti F; Stathopoulos ES; Kyriakou DS
    Eur J Histochem; 2005; 49(1):27-32. PubMed ID: 15823791
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.
    Della Porta MG; Alessandrino EP; Bacigalupo A; van Lint MT; Malcovati L; Pascutto C; Falda M; Bernardi M; Onida F; Guidi S; Iori AP; Cerretti R; Marenco P; Pioltelli P; Angelucci E; Oneto R; Ripamonti F; Bernasconi P; Bosi A; Cazzola M; Rambaldi A;
    Blood; 2014 Apr; 123(15):2333-42. PubMed ID: 24558201
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
    Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D
    Leuk Lymphoma; 2019 Jun; 60(6):1522-1527. PubMed ID: 30499738
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.
    Pardanani A; Lasho TL; Finke CM; Rajkumar SV; Singh PP; Ketterling RP; Hanson CA; Katzmann JA; Tefferi A
    J Clin Oncol; 2012 Apr; 30(10):1087-94. PubMed ID: 22331938
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
    Falantes JF; Márquez-Malaver FJ; Knight T; Calderón-Cabrera C; Martino ML; González J; Montero I; Espigado I; Pérez-Simón JA
    Leuk Lymphoma; 2017 Aug; 58(8):1893-1902. PubMed ID: 27951729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients.
    Saeed L; Patnaik MM; Begna KH; Al-Kali A; Litzow MR; Hanson CA; Ketterling RP; Porrata LF; Pardanani A; Gangat N; Tefferi A
    Blood Cancer J; 2017 Mar; 7(3):e550. PubMed ID: 28362440
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
    Nazha A; Narkhede M; Radivoyevitch T; Seastone DJ; Patel BJ; Gerds AT; Mukherjee S; Kalaycio M; Advani A; Przychodzen B; Carraway HE; Maciejewski JP; Sekeres MA
    Leukemia; 2016 Nov; 30(11):2214-2220. PubMed ID: 27311933
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes.
    Ma X; Wang R; Galili N; Mayne ST; Wang SA; Yu H; Raza A
    Cancer Causes Control; 2011 Apr; 22(4):623-9. PubMed ID: 21287258
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
    Verstovsek S; Kantarjian H; Estey E; Aguayo A; Giles FJ; Manshouri T; Koller C; Estrov Z; Freireich E; Keating M; Albitar M
    Leukemia; 2001 Aug; 15(8):1165-70. PubMed ID: 11480557
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.
    Kern W; Bacher U; Haferlach C; Alpermann T; Schnittger S; Haferlach T
    Cytometry B Clin Cytom; 2015; 88(3):154-64. PubMed ID: 25581461
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic factors and risk models in myelodysplastic syndromes.
    Komrokji RS; Padron E; Lancet JE; List AF
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S295-9. PubMed ID: 24290214
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
    Kobayashi S; Ueda Y; Nannya Y; Shibayama H; Tamura H; Ogata K; Akatsuka Y; Usuki K; Ito Y; Okada M; Suzuki T; Hata T; Matsuda A; Tohyama K; Kakumoto K; Koga D; Mitani K; Naoe T; Sugiyama H; Takaku F
    Cancer Biomark; 2016 Mar; 17(1):21-32. PubMed ID: 27062571
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
    Cluzeau T; Mounier N; Karsenti JM; Richez V; Legros L; Gastaud L; Garnier G; Re D; Montagne N; Gutnecht J; Gabriel Fuzibet J; Auberger P; Raynaud S; Cassuto JP
    Am J Hematol; 2013 Sep; 88(9):780-3. PubMed ID: 23757315
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.
    Mohamedali A; Gäken J; Twine NA; Ingram W; Westwood N; Lea NC; Hayden J; Donaldson N; Aul C; Gattermann N; Giagounidis A; Germing U; List AF; Mufti GJ
    Blood; 2007 Nov; 110(9):3365-73. PubMed ID: 17634407
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.
    Neukirchen-Strapatsas J; Tuechler H; Porta MD; Fenaux P; Guerci A; Haas R; Rossi M; Sapena R; Sperr WR; Strupp C; Stamatoullas A; Valent P; Germing U; Bennett JM
    Leuk Res; 2019 Feb; 77():8-13. PubMed ID: 30605856
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
    Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.